Psyence Biomedical ltd (PBM) - News Archive

The Phase IIb trial, whose kickoff has been long-anticipated, is designed to study the influence of psilocybin in mitigating the symptoms and effects of Adjustment Disorder following severe cancer diagnoses in the palli...

In significant news from the revolutionary niche of psychedelic medicine, Psyence Group Inc. (Psyence Group), a trailblazer in utilizing nature-derived psilocybin for mental health and wellbeing, announced that its NASD...

Subsidiary Psyence Australia Pty Ltd is leading the endeavor after receiving approval from the Australian Health Research Ethics Committee (HREC) to begin the Phase IIb study in Melbourne, Australia. Subsequently, the r...

Psyence Group Successfully Completes Strategic Restructuring of Non-Clinical BusinessTORONTO, March 26, 2024 - Psyence Group Inc. (Psyence), a leading company in the field of psychedelic medicine, today confirmed the su...

In a breakthrough study published in the renowned journal Molecular Psychiatry, the comparative therapeutic benefits of nature-derived psilocybin and its synthetic counterpart have been explored. Through meticulous rese...

Psyence Group Inc. (CSE: PSYG), a leading clinical-stage life science biotechnology company specializing in the use of nature-derived psilocybin for mental health and wellbeing, is pleased to announce that its associate...

In a recent press release, Psyence Biomedical Ltd., a leading clinical-stage life science biotechnology company, highlighted its recent progress and outlined key future milestones in pioneering the use of nature-derived...

Psyence Group, a leading innovator in the field of psychedelic medicine, recently provided a corporate update following the successful spin-out of its therapeutic division. The company closed the business combination of...

Psyence Biomedicals Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb StudyNEW YORK, March 06, 2024 - Psyence Biomedical Ltd (NASDAQ:PBM) (Psyence Biomed or th...